Kisqali is not chemotherapy. It belongs to a group of drugs called kinase inhibitors. It’s a type of targeted therapy for breast cancer. Kisqali belongs to a group of drugs called kinase inhibitors.

In a long awaited approveall, The Food and Drug Administration (FDA) has just approved the drug Kisqali (ribociclib) in ...

Novartis' CDK4/6 inhibitor Kisqali has claimed a broad FDA approval in early breast cancer that could give it an edge over class rival Verzenio from Eli Lilly. The US regulator has cleared Kisqali ...